Jason Westin, MD
Enriched profileProfessor, Department of Lymphoma/Myeloma, Division of Cancer Medicine; Director, Lymphoma Clinical Research Program; Section Chief, Aggressive Lymphoma · The University of Texas MD Anderson Cancer Center
Jason Westin is Professor, Department of Lymphoma/Myeloma, Division of Cancer Medicine; Director, Lymphoma Clinical Research Program; Section Chief, Aggressive Lymphoma at The University of Texas MD Anderson Cancer Center. OpenAlex indexes 658 publications with 30,280 citations (h-index 58); ClinicalTrials.gov lists 13 registered studies with this person as an investigator.
Data verified 14 Aug 2026
Overview
Updated 27 Aug 2026
Jason R. Westin, MD, is Professor, Department of Lymphoma/Myeloma, Division of Cancer Medicine at The University of Texas MD Anderson Cancer Center, Houston, TX. The public record shows 658 publications with 30,280 citations (h-index 58), centered on Lymphoma Diagnosis and Treatment, CAR-T cell therapy research, Chronic Lymphocytic Leukemia Research. It also documents an investigator role on 13 registered clinical trials, industry payments reported by 28 companies.
- Most recent indexed publication: 2026 · Blood
- Top research focus: Lymphoma Diagnosis and Treatment
- 13 registered trials on ClinicalTrials.gov
- Open Payments reporting from 28 companies
Generated from the cited public record · current as of 27 Aug 2026. Every fact links its source below.
Indications focus
from trials led + research topicsResearch focus
OpenAlex concept fingerprintDrugs & molecules
across trials, industry payments and publicationsWorks with
trial sponsors and companies reporting paymentsScholarship
indexed output and impact (OpenAlex)Distinct works indexed by OpenAlex, matched via ORCID; 71 in PubMed.
Total citations across indexed works.
Hirsch index (OpenAlex). i10-index 199.
Clinical & industry
trials, payments and federal fundingFederally funded research awards.
Public positions
sourced statements on record- Testified before U.S. Senate Finance Committee
"Drug Shortages: Examining Supply Challenges, Impacts, and Policy Solutions from a Federal Health Program Perspective," December 5, 2023 …
2023verifiedCorroborated by findmyKOL. We matched this record across two or more independent public sources (or a verified ORCID / NPI identifier bridge) before attributing it to this person.How we verify →finance.senate.gov ↗
Contact
The practice address and phone this provider lists in the federal NPPES (CMS) registry.
Practice address
Telephone
Practice address and telephone from the federal NPPES registry.
Sign in to view contact details →Clinical trials
Updated 27 Aug 2026
Listed as an investigator on 13 registered studies on ClinicalTrials.gov. The most recent:
- Consolidation of First-Line MRD+ Remission With Cema-cel in Patients With LBCL
Sponsor: Allogene Therapeutics
- A Study of Axicabtagene Ciloleucel and Glofitamab as Second-Line Therapy for Relapsed or Refractory Patients With Large B Cell Lymphoma
Sponsor: M.D. Anderson Cancer Center
- A Phase II Trial of Mosunetuzumab, Polatuzumab, Tafasitamab, and Lenalidomide in Patients With Relapsed B-cell NHL
Sponsor: M.D. Anderson Cancer Center
Industry payments
Updated 27 Aug 2026
28 companies reported payments to CMS in program years 2021–2025. These are public disclosures, not judgments. The latest:
- Merck Sharp & Dohme LLCProgram year20259 payments$20,393openpaymentsdata.cms.gov ↗
- Genentech USA, Inc.Program year20257 payments
- Incyte CorporationProgram year20256 payments
Medicare prescribing footprint (2024)
The drugs this prescriber writes for Medicare patients, grouped by drug class and therapeutic area. Every percentage is a share of their total prescribing, so you can see what they prescribe most. These are proportions, not patient counts or dollar amounts. No condition is inferred: the claims record what was prescribed, never why.
Anti-infectives
42.2%Herpesvirus Nucleoside Analog DNA Polymerase Inhibitor23.6%Valacyclovir100%Part D≥17 patientsShort-acting sulfonamides11.8%Sulfamethoxazole-Trimethoprim100%Part D<11 patientsMetabolism & gastrointestinal
34.2%Corticosteroid13%Prednisone100%Part D≥17 patientsSerotonin-3 Receptor Antagonist11.8%Ondansetron Hcl100%Part D≥15 patientsCancer & immunology
16.1%Thalidomide Analog8.7%Revlimid100%Part D<11 patientsKinase inhibitor7.5%Calquence100%Part D<11 patients
Drug classes come from the WHO ATC and U.S. National Library of Medicine (RxClass) classifications; prescribing counts come from the CMS Medicare Part D Prescribers file. Each drug is counted once, under its primary class. Medicare fee-for-service only, so no Medicare Advantage, commercial, or pediatric prescribing is included. CMS publishes this data about 17 months after the fact.
NIH funding
We didn't find any NIH-funded research awards for this person in NIH RePORTER. Why? →
Congress activity
Updated 27 Aug 2026
198 congress contributions (2010–2025) across AACR, ASCO, ASH, ASTRO per OpenAlex. The most recent:
- Abstract LB369: Final results of a phase I trial of evorpacept (ALX148), lenalidomide, and rituximab for patients with B-cell non-Hodgkin lymphoma
AACR Annual Meeting
AACR2025Co-authorLate-breaking
Published abstracts are attributed via the same ORCID-disambiguated authorship as publications, so each is DOI-verified. Podium roles (invited talks, session chairs) and oral/poster type are added as program data is confirmed.
Publications
Updated 27 Aug 2026
Their five most recent publications, matched to their ORCID record and linked to PubMed.
- A Patient-Derived Xenograft Repository Capturing Clinical and Molecular Heterogeneity of Large B-cell Lymphoma.
Blood cancer discovery
Article2026 - Clinical trial success rate in lymphoma: fate of trials and agents from 2000 to 2019.
Blood advances
Article2026
Most-cited works
by citation count (OpenAlex)Network
Updated 27 Aug 2026
The people this person publishes with most, by number of co-authored papers. Names link to their own profile when we have one.
Online presence
Updated 27 Aug 2026
This person's own public accounts first, then places where others mention them. Two different things, listed separately.
Owned accounts
public accounts run by this person- LinkedIn
linkedin.com/in/jason-westin-md-ms-fasco-632a7773
verifiedCorroborated by findmyKOL. We matched this record across two or more independent public sources (or a verified ORCID / NPI identifier bridge) before attributing it to this person.How we verify →linkedin.com ↗ - ResearchGate
researchgate.net/profile/Jason-Westin
verifiedCorroborated by findmyKOL. We matched this record across two or more independent public sources (or a verified ORCID / NPI identifier bridge) before attributing it to this person.How we verify →researchgate.net ↗ - LinkedIn
linkedin.com/in/jason-westin-632a7773
provisionalFound in a cited public source but not yet independently corroborated. Published as a labeled candidate and queued for verification.How we verify →linkedin.com ↗
Mentions by others
where others cite or feature them- LinkedIn
linkedin.com/posts/mdandersoncancercenter_meet-lymphoma-oncologist-jason-westin-md-activity-7170457108235104256-KGke
verifiedCorroborated by findmyKOL. We matched this record across two or more independent public sources (or a verified ORCID / NPI identifier bridge) before attributing it to this person.How we verify →linkedin.com ↗ - Other
society.asco.org/people/jason-r-westin-md
provisionalFound in a cited public source but not yet independently corroborated. Published as a labeled candidate and queued for verification.How we verify →society.asco.org ↗ - Other
vjhemonc.com/speaker/jason-westin
provisionalFound in a cited public source but not yet independently corroborated. Published as a labeled candidate and queued for verification.How we verify →vjhemonc.com ↗
We list an account only when the public record ties it to this person. verified means we've confirmed the match in more than one place; provisional means it looks right but we're still confirming.
Background & recognition
Updated 27 Aug 2026
Credentials, appointments and honors, newest first, each linked to the public source it came from.
Education
degrees and training on record- verifiedCorroborated by findmyKOL. We matched this record across two or more independent public sources (or a verified ORCID / NPI identifier bridge) before attributing it to this person.How we verify →icksh.org ↗
- verifiedCorroborated by findmyKOL. We matched this record across two or more independent public sources (or a verified ORCID / NPI identifier bridge) before attributing it to this person.How we verify →faculty.mdanderson.org ↗
- M.S. in Clinical and Translational Sciences
University of Texas Graduate School of Biomedical Sciences, Houston, TX
2015verifiedCorroborated by findmyKOL. We matched this record across two or more independent public sources (or a verified ORCID / NPI identifier bridge) before attributing it to this person.How we verify →icksh.org ↗ - verifiedCorroborated by findmyKOL. We matched this record across two or more independent public sources (or a verified ORCID / NPI identifier bridge) before attributing it to this person.How we verify →icksh.org ↗
- verifiedCorroborated by findmyKOL. We matched this record across two or more independent public sources (or a verified ORCID / NPI identifier bridge) before attributing it to this person.How we verify →icksh.org ↗
- verifiedCorroborated by findmyKOL. We matched this record across two or more independent public sources (or a verified ORCID / NPI identifier bridge) before attributing it to this person.How we verify →icksh.org ↗
- verifiedCorroborated by findmyKOL. We matched this record across two or more independent public sources (or a verified ORCID / NPI identifier bridge) before attributing it to this person.How we verify →icksh.org ↗
Editorial & leadership roles
journal and society appointments- verifiedCorroborated by findmyKOL. We matched this record across two or more independent public sources (or a verified ORCID / NPI identifier bridge) before attributing it to this person.How we verify →faculty.mdanderson.org ↗
- Association Treasurer
American Society of Clinical Oncology Association Board of Directors, 6/2022-6/2023
2023verifiedCorroborated by findmyKOL. We matched this record across two or more independent public sources (or a verified ORCID / NPI identifier bridge) before attributing it to this person.How we verify →icksh.org ↗ - verifiedCorroborated by findmyKOL. We matched this record across two or more independent public sources (or a verified ORCID / NPI identifier bridge) before attributing it to this person.How we verify →icksh.org ↗
Awards & honors
honors on the public record- verifiedCorroborated by findmyKOL. We matched this record across two or more independent public sources (or a verified ORCID / NPI identifier bridge) before attributing it to this person.How we verify →faculty.mdanderson.org ↗
- verifiedCorroborated by findmyKOL. We matched this record across two or more independent public sources (or a verified ORCID / NPI identifier bridge) before attributing it to this person.How we verify →icksh.org ↗
- verifiedCorroborated by findmyKOL. We matched this record across two or more independent public sources (or a verified ORCID / NPI identifier bridge) before attributing it to this person.How we verify →icksh.org ↗
Secondary affiliations
appointments beyond the home institution- verifiedCorroborated by findmyKOL. We matched this record across two or more independent public sources (or a verified ORCID / NPI identifier bridge) before attributing it to this person.How we verify →icksh.org ↗
- Clinical Residency
Assistant Professor, Division of Internal Medicine, University of North Carolina, Chapel Hill, NC, 2002-2006
2006verifiedCorroborated by findmyKOL. We matched this record across two or more independent public sources (or a verified ORCID / NPI identifier bridge) before attributing it to this person.How we verify →icksh.org ↗
Media & interviews
press, podcasts and appearances- verifiedCorroborated by findmyKOL. We matched this record across two or more independent public sources (or a verified ORCID / NPI identifier bridge) before attributing it to this person.How we verify →vjhemonc.com ↗
- verifiedCorroborated by findmyKOL. We matched this record across two or more independent public sources (or a verified ORCID / NPI identifier bridge) before attributing it to this person.How we verify →pharmaphorum.com ↗
- verifiedCorroborated by findmyKOL. We matched this record across two or more independent public sources (or a verified ORCID / NPI identifier bridge) before attributing it to this person.How we verify →connection.asco.org ↗
Every item links to where we found it. verified means we've confirmed it in more than one place; provisional means we found it and are still confirming.
Similar KOLs
Other experts from the same institution or the same specialty.
Hagop Kantarjian, MD
The University of Texas MD Anderson Cancer Center
Gabriel Hortobagyi, MD
The University of Texas MD Anderson Cancer Center
Jaffer Ajani, MD
The University of Texas MD Anderson Cancer Center
Funda Meric-Bernstam, MD
The University of Texas MD Anderson Cancer Center